Vaccine hesitancy after taking the first dose of COVID-19 vaccine

Abstract

Background: Coronavirus disease 2019 (COVID-19) vaccination campaigns are trying to curb the pandemic by vaccinating as many individuals and as quickly as possible. The speed of immunization depends upon the availability of the vaccine and vaccine uptake by the communities, which in turn is related to vaccine hesitancy, the safety/efficacy profile of the vaccines, and adverse events following immunization (AEFI) Objectives: (i) To study the AEFI experienced by vaccine recipients and (ii) to assess the subjective effect of these AEFI on the vaccine recipients, that is, perceived disability and opinion regarding taking the vaccine’s second dose Methods: This was a cross-sectional study conducted at a tertiary care hospital where a questionnaire was distributed to the medical students who had taken at least one dose of a COVID-19 vaccine Results: Out of 208 participants, more than three-quarters ( n = 169, 81.2%) experienced AEFI symptoms within 12 hours of vaccination. The commonest symptoms were pain at the injection site ( n = 173, 83.2%), body aches ( n = 91, 43.8%), fever ( n = 88, 42.3%), weakness ( n = 86, 41.3%), and headache ( n = 72, 34.6%). A majority of the participants reported complete recovery within 13–24 hours. Complete recovery was seen in all the study participants, and no serious event was seen. Twenty (10%) participants reported that they were not confident in taking the second dose of the vaccine Conclusions: The disability perceived by the vaccine recipients should be taken into consideration in a vaccine with a multi-dose schedule. Pitfalls in alleviating the immunization-related anxiety should be identified and addressed.

COVID-19 vaccine acceptance in Notoprajan, Yogyakarta, Indonesia: a lesson learned from the pandemic

“…3, September 2023: 924-931 930 the AEFI incidence of the COVID-19 vaccine at doses 1 and 2 was comparable to the trial results and in the community [27]. Other studies, on the other hand, found that because they had AEFI at dose 1, people were hesitant to receive dose 2 [9], [16], [28], [29].…”

Acceptance of COVID-19 Vaccines in India: A Systematic Review and Meta-Analysis

“…Hence, a subgroup analysis was conducted based on the gender and residence that might differ significantly across the studies. Additionally, M et al [27] SJ et al [28] M et al [29] SA et al [30] r GC et al [31] N et al [32] ta S et al [33] S et al [34] a P et al [35] a Y et al [36] A et al [37] S et al [38] N et al [39] l Y et al [40] arathi A et al…”

“… Acceptance of the COVID-19 vaccine in India according to residence, as shown in the form of a forest plot [ 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 ]. …”

The conundrum of new coronavirus variants and poor uptake of booster dose: building a narrative against vaccine hesitancy in Pakistan

“…This may include mild fever and shoulder pain after 12-48 hours of immunization [15] . A recent study conducted in India on the assessment of vaccine hesitancy after taking the first dose of COVID-19 provides evidence for vaccine reluctance to second dose due to post-immunization adverse events [16] . Recent data collected in Saudi Arabia proved that 24.1% of people were hesitant based on the long waiting hours experienced at vaccination centers [17] .…”